{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:46:17Z","timestamp":1762019177764,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.toxicon.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T21:01:26Z","timestamp":1580936486000},"page":"67-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF)"],"prefix":"10.1016","volume":"176","author":[{"given":"Robert","family":"Webb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet C.","family":"Skerry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca L.","family":"Guernieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Stawicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2020.02.001_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/toxins2040665","article-title":"Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering","volume":"4","author":"Binz","year":"2010","journal-title":"Toxins"},{"issue":"8","key":"10.1016\/j.toxicon.2020.02.001_bib2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.toxicon.2006.02.013","article-title":"Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey","volume":"47","author":"Boles","year":"2006","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2020.02.001_bib3","first-page":"310","article-title":"Identification of a novel new botulinum neurotoxin gene cluster in Enterococcus","volume":"592","author":"Brunt","year":"2018","journal-title":"FEBS Lett. 2018"},{"issue":"42","key":"10.1016\/j.toxicon.2020.02.001_bib4","first-page":"1454","article-title":"Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins","volume":"60","year":"2011","journal-title":"MMWR (Morb. Mortal. Wkly. Rep.)"},{"issue":"7","key":"10.1016\/j.toxicon.2020.02.001_bib5","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/iai.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.toxicon.2020.02.001_bib6","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1038\/s41467-019-10732-w","article-title":"A neurotoxin that specifically targets Anopheles mosquitoes","volume":"10","author":"Contreras","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.toxicon.2020.02.001_bib7","series-title":"Therapy with Botulinum Neurotoxin","first-page":"93","article-title":"Immunogenicity of the toxins of Clostridium botulinum","author":"Hatheway","year":"1994"},{"key":"10.1016\/j.toxicon.2020.02.001_bib8","first-page":"1035","article-title":"Clostridium botulinum and Clostridium tetani","volume":"vol. 8","author":"Johnson","year":"2005"},{"key":"10.1016\/j.toxicon.2020.02.001_bib9","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1128\/iai.65.11.4586-4591.1997","article-title":"Induction of an immune response by oral administration of recombinant botulinum toxin","volume":"65","author":"Kiyatkin","year":"1997","journal-title":"Infect. Immun."},{"key":"10.1016\/j.toxicon.2020.02.001_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pbiomolbio.2015.02.004","article-title":"Diverse binding modes, same goal: the receptor recognition mechanism of botulinum neurotoxin","volume":"117","author":"Lam","year":"2015","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"3","key":"10.1016\/j.toxicon.2020.02.001_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.febslet.2014.12.018","article-title":"Botulinum neurotoxin homologs in non-Clostridium species","volume":"589","author":"Mansfield","year":"2015","journal-title":"FEBS Lett. Jan 30"},{"issue":"5","key":"10.1016\/j.toxicon.2020.02.001_bib12","first-page":"1","article-title":"An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock","volume":"6","author":"Morefield","year":"2008","journal-title":"J. Immune Base Ther. Vaccine"},{"year":"2017","series-title":"Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature","author":"Peck","key":"10.1016\/j.toxicon.2020.02.001_bib13"},{"key":"10.1016\/j.toxicon.2020.02.001_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/IAI.00843-07","article-title":"Recombinant holotoxoid vaccine against botulism","volume":"76","author":"Pier","year":"2008","journal-title":"Infect. Immun. 2008"},{"key":"10.1016\/j.toxicon.2020.02.001_bib15","first-page":"32","article-title":"Hsp90 and Thioredoxin-Thioredoxin Reductase enable the catalytic activity of Clostridial neurotoxins inside nerve terminals","volume":"147","author":"Pirazzini","year":"2018","journal-title":"Toxicon. 2018"},{"issue":"6","key":"10.1016\/j.toxicon.2020.02.001_bib16","first-page":"827","article-title":"Enhancing toxin based vaccines against botulism","volume":"36","author":"Przedpelski","year":"2018","journal-title":"Infect. Vaccine. 1"},{"key":"10.1016\/j.toxicon.2020.02.001_bib17","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1128\/IAI.00382-13","article-title":"Enhancing the protective immune response against botulism","volume":"81","author":"Przedpelski","year":"2013","journal-title":"Infect. Immun."},{"issue":"6","key":"10.1016\/j.toxicon.2020.02.001_bib18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/j.1471-4159.2009.06298.x","article-title":"Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilizing the three isoforms of SV2 as second receptor","volume":"110","author":"Rummel","year":"2009","journal-title":"J. Neurochem."},{"issue":"Pt A","key":"10.1016\/j.toxicon.2020.02.001_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxicon.2015.09.009","article-title":"The long journey of botulinum neurotoxins into the synapse","volume":"107","author":"Rummel","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2020.02.001_bib20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: past history and recent developments","volume":"12","author":"Rusnak","year":"2009","journal-title":"Hum. Vaccine"},{"issue":"9","key":"10.1016\/j.toxicon.2020.02.001_bib21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/CVI.00080-10","article-title":"Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1","volume":"17","author":"Sanford","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"issue":"11","key":"10.1016\/j.toxicon.2020.02.001_bib23","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.vaccine.2012.01.035","article-title":"Preclinical safety assessment of recombinant botulinum vaccine A\/B (rBV A\/B)","volume":"30","author":"Shearer","year":"2012","journal-title":"Vaccine. 2"},{"key":"10.1016\/j.toxicon.2020.02.001_bib24","doi-asserted-by":"crossref","first-page":"D33","DOI":"10.1016\/j.vaccine.2009.08.059","article-title":"Botulism and vaccines for its prevention","volume":"27","author":"Smith","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.toxicon.2020.02.001_bib25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erv.13.37","article-title":"What next for botulism vaccine development?","volume":"12","author":"Webb","year":"2013","journal-title":"Expert Rev Vaccines. May"},{"key":"10.1016\/j.toxicon.2020.02.001_bib26","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.vaccine.2009.05.030","article-title":"Production of catalytically inactive BoNT\/A1 holoprotein and comparison with BoNT\/A1 subunit vaccines against toxin subtypes A1, A2, and A3","volume":"16","author":"Webb","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.toxicon.2020.02.001_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/toxins9090269","article-title":"Recombinant botulinum neurotoxin Hc subunit (BoNT Hc) and catalytically inactive Clostridium botulinum holoproteins (ciBoNT HPs) as vaccine candidates for the prevention of botulism","volume":"9","author":"Webb","year":"2017","journal-title":"Toxins"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010120300325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010120300325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:14:03Z","timestamp":1758575643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010120300325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":26,"alternative-id":["S0041010120300325"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2020.02.001","relation":{},"ISSN":["0041-0101"],"issn-type":[{"type":"print","value":"0041-0101"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF)","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}